Atara Biotherapeutics(ATRA) - 2021 Q2 - Quarterly Report

Financial Performance - Total current assets decreased from $523.3 million as of December 31, 2020, to $392.3 million as of June 30, 2021, representing a decline of approximately 25%[19] - The company reported a net loss of $83.8 million for the three months ended June 30, 2021, compared to a net loss of $77.5 million for the same period in 2020, reflecting an increase in losses of approximately 8%[22] - For the six months ended June 30, 2021, Atara Biotherapeutics reported a net loss of $162.1 million, compared to a net loss of $151.0 million for the same period in 2020, reflecting an increase in losses[27] - The accumulated deficit increased from $1.1 billion as of December 31, 2020, to $1.3 billion as of June 30, 2021[19] - The company incurred stock-based compensation expenses of $26.1 million for the six months ended June 30, 2021, slightly down from $26.6 million in the prior year[27] - The company reported total stock-based compensation expense of $26.075 million for the six months ended June 30, 2021[89] - The company has incurred losses and negative cash flows from operations since inception and anticipates continued losses in the foreseeable future[132] - The company reported a net loss of $162.1 million for the six months ended June 30, 2021, continuing its trend of significant operating losses since inception[159] Revenue and Financing - The company had no revenues from product commercialization, as it currently has no approved products[16] - License and collaboration revenue for the six months ended June 30, 2021, was $7.4 million, with no revenue reported for the same period in 2020[22] - The company anticipates continued substantial losses and will require additional financing to achieve its goals[16] - The company expects existing cash and short-term investments will be sufficient to fund planned operations for at least the next twelve months[33] - Existing cash and short-term investments are expected to fund planned operations into 2023, but substantial additional funding will be required for regulatory approvals and commercialization[141] - The company has no committed external source of funds other than potential reimbursements and milestone payments under existing agreements[170] Research and Development - Research and development expenses for the three months ended June 30, 2021, were $68.5 million, an increase of 11% compared to $61.6 million for the same period in 2020[22] - The company is focused on advancing its product candidates through clinical studies and expects to face regulatory scrutiny and challenges in commercialization[16] - The company plans to continue investment in the development of product candidates, including advancing early-stage programs to human clinical studies over the next several years[122] - Total research and development expenses for the six months ended June 30, 2021, were $132.5 million, an increase of $13.3 million compared to $119.2 million in the same period of 2020[123] - The company has incurred significant research and development expenses and expects these to increase as it continues to develop product candidates[160] Clinical Development and Regulatory Approval - The lead program, tab-cel®, is in Phase 3 development for EBV-driven post-transplant lymphoproliferative disease[91] - The company expects to complete the BLA submission for tab-cel® in the first quarter of 2022, with potential commercialization in the U.S. anticipated in the second half of 2022[1] - The anticipated completion of the BLA filing for tab-cel® is expected in the first quarter of 2022, with a potential approval decision in the second half of 2022[162] - The FDA has provided feedback on the next steps required for the BLA submission for tab-cel®, including a Type B CMC meeting and a Type B clinical meeting[188] - The company is in ongoing discussions with potential partners for the commercialization of tab-cel® in Europe[1] - The company has not yet demonstrated the ability to successfully complete any Phase 2 or Phase 3 clinical studies or obtain regulatory approval for its product candidates[161] Challenges and Risks - The ongoing COVID-19 pandemic has adversely affected the company's business operations, including delays in clinical trials and patient enrollment[176] - The company may face significant costs associated with commercializing any approved product candidate, which could impact profitability[166] - The company is subject to risks associated with the development of new products, including unforeseen expenses and delays[140] - The company faces challenges in developing and commercializing T-cell immunotherapies, including regulatory scrutiny and the need for consistent manufacturing processes[192] - Delays in clinical studies can harm product approval prospects and increase development costs, jeopardizing revenue generation[207] Stock and Equity - As of June 30, 2021, total stockholders' equity was $331.5 million, a decrease from $462.3 million as of December 31, 2020[25] - The company issued pre-funded warrants to purchase 2,945,026 shares of common stock in July 2019, with outstanding warrants totaling 2,888,526 shares as of June 30, 2021[76] - A total of 16,773,438 shares were reserved for issuance under the 2014 Equity Incentive Plan, with 3,559,544 shares available for future grant[81] - As of June 30, 2021, there was $76.7 million of unrecognized stock-based compensation expense related to RSUs expected to be recognized over a weighted average period of 2.8 years[83] Agreements and Collaborations - The company has entered into a research, development, and license agreement with Bayer AG, granting Bayer an exclusive license related to ATA2271 and ATA3271[30] - The company received an upfront cash payment of $45.0 million from Bayer for an exclusive license grant, along with an additional $15.0 million reimbursement for research activities[53] - The company is entitled to receive up to $610.0 million in milestone payments upon achieving certain development and regulatory milestones related to the licensed products[53] - The company has entered into various license and collaboration agreements, including those with QIMR Berghofer, which involve milestone and royalty payments based on future product sales[68] Cash Flow and Liquidity - Cash, cash equivalents, and restricted cash at the end of the period were $125.3 million, up from $75.9 million at the end of June 30, 2020[27] - As of June 30, 2021, cash and cash equivalents totaled $123.856 million, a decrease from $200.404 million as of December 31, 2020[48] - As of June 30, 2021, total cash, cash equivalents, and short-term investments amounted to $373.4 million, a decrease of 25.4% from $500.7 million as of December 31, 2020[134] Operational Expenses - General and administrative expenses increased to $19.4 million for the three months ended June 30, 2021, compared to $16.4 million in the same period of 2020, driven by activities to support the anticipated tab-cel® launch[127] - Employee and overhead expenses rose to $48.1 million for the three months ended June 30, 2021, from $40.6 million in the same period of 2020, due to higher compensation-related costs and increased headcount[125]